All In Biotech

Drug Trial Radar · NCT06823284

To Assess the Bioavailability of TK-254RX in Comparison with Oral Flurbiprofen Tablets and the Adhesion of TK-254RX in Healthy Subjects

Characterization of Relative Bioavailability of a Newly Developed Esflurbiprofen Topical System (EFTS) in Comparison with a Marketed Oral Flurbiprofen-containing Tablet Formulation After Multiple-dose Administration Including EFTS Adhesion Assessment - a Phase I, Open-label, Randomized, 2-period, Cross-over Study in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Mar 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

26

Actual

Start

Jan 21, 2025

Primary completion

Feb 12, 2025

Study completion Feb 24, 2025

Sponsor

Lead sponsor
Teikoku Seiyaku Co., Ltd.Industry
Sponsor type
Industry
Collaborators
SocraTec R&D GmbH; SocraMetrics GmbH; HWI pharma services GmbH
First posted
Feb 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a single-center, open-label, multiple-dose trial performed in a 2-period, 2- sequence-cross-over design in healthy volunteers. The primary purpose of this study is to assess non-superiority of the bioavailability of TK-254RX compared with that of a marketed oral flurbiprofen-containing tablet formulation in healthy volunteers in a 2-period, 2- sequence-cross-over design and evaluate adhesion of TK-254RX. Secondary purpose is to assess safety of TK-254RX and residual amount of the patch.

Conditions

  • Healthy

Interventions

  • Esflurbiprofen Topical SystemDrug

    The total of two TK-254RX per day for 5 days (one patch applied to left and right lower leg above ankle)

  • Flurbiprofen tabletDrug

    3 tablets per day for 4 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the plasma concentration versus time curve over 24 hours of S-flurbiprofen for TK-254RX and tablet under steady-state conditionsTime frame: Day 5 to Day 6
  2. Peak Plasma Concentration of S-flurbiprofen for TK-254RX and tablet under steady-state conditionsTime frame: Day 5 to Day 6
  3. Characterization of patch adhesionTime frame: Day 1 to Day 6

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • SocraTec R&D GmbH Clinical Pharmacology Unit

    Mainzerhofplatz 14, Erfurt, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.